United Health Products, Inc. (UEEC)
OTCMKTS · Delayed Price · Currency is USD
0.0365
+0.0025 (7.35%)
At close: Oct 29, 2026
United Health Products Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
9.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 37.50K | 37.44K | 63,459.32% |
| Dec 31, 2021 | 59.00 | -584.00 | -90.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meihua International Medical Technologies | 61.79M |
| Medite Cancer Diagnostics | 8.13M |
| Encision | 6.30M |
| Lancer Orthodontics | 6.19M |
| Reflect Scientific | 1.72M |
| Standard Dental Labs | 415.61K |
| Hear AtLast Holdings | 93.20K |
| Cardiac Biotech Solutions | 50.37K |
United Health Products News
- 11 months ago - United Health Products Quarterly report: Q3 2025 - Filings
- 1 year ago - United Health Products to Present at the Life Sciences Virtual Investor Forum September 18th - GlobeNewsWire
- 1 year ago - United Health Products Quarterly report: Q2 2025 - Filings
- 1 year ago - United Health Products Quarterly report: Q1 2025 - Filings
- 1 year ago - United Health Products Annual report: Q4 2024 - Filings
- 1 year ago - United Health Products provides update on clinical study process - TheFly
- 1 year ago - United Health Products Provides Update on Clinical Study Process - GlobeNewsWire
- 1 year ago - United Health Products Quarterly report: Q3 2024 - Filings